New Delhi: The Senores Pharmaceuticals Ltd has received very good response from the investors as the issue got subscribed 1.78 times on December 20, 2024, the first day of bidding. The NSE data showed that the Initial Public Offer (IPO) fetched bids for 1,51,51,550 shares against 85,34,681 shares on offer. The Retail Individual Investors (RIIs) portion received 7.19 times subscription while it was 1.67 times in the non-institutional investors part. The Qualified Institutional Buyers (QIBs) quota got subscribed 1 per cent. The IPO has a price range of Rs 372-391 per share.
Senores Pharmaceuticals Ltd on Thursday raised nearly Rs 261 crore from anchor investors, which included fund houses like Aditya Birla Sun Life Insurance Company, Troo Capital, SBI General Insurance Company, and ICICI Prudential Mutual Fund, and Mahindra Manulife Mutual Fund.
Senors Pharmaceuticals IPO GMP
The Ahmedabad-based company’s IPO will close for subscription on Tuesday, December 24. Senores Pharmaceuticals IPO GMP stood at Rs 215 on December 23 morning, according to investorgain. With the price band fixed at Rs 391, the shares are projected to be listed at R s606, indicating nearly 55 per cent listing gains.
Senores Pharmaceuticals IPO allotment, listing
- Senores Pharmaceuticals IPO Opened on December 20
- IPO closes on December 24
- Senores Pharmaceuticals IPO Allotment expected on December 26
- Refunds process likely to begin on December 27
- The shares are expected to be credited to the Demat accounts of successful investors on December 27
- Shares to list on BSE and NSE. Tentative date – December 30
The Senores Pharmaceuticals IPO is a combination of fresh issuance of shares worth Rs 500 crore of fresh issue of 1.28 crore shares and offer for sale of 0.21 crore shares aggregating to Rs 82.11 crore.
Book running lead managers of the Senores Pharmaceuticals IPO: Ambit Private Limited, Nuvama Wealth Management Limited and Equirus Capital Private Limited. Link Intime India Private Ltd is the registrar for the issue.
(Disclaimer: This article is only meant to provide information. News9 does not recommend buying or selling shares or subscriptions of any IPO and Mutual Funds.)
Comments are closed.